{
    "Trade/Device Name(s)": [
        "Access\u00ae BR Monitor",
        "Access BR Monitor Calibrators",
        "Access Immunoassay Systems"
    ],
    "Submitter Information": "Beckman Coulter, Inc.",
    "510(k) Number": "K072612",
    "Predicate Device Reference 510(k) Number(s)": [
        "K033036"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "MOI",
        "JIT"
    ],
    "Summary Letter Date": "October 26, 2007",
    "Summary Letter Received Date": "September 17, 2007",
    "Submission Date": "September 14, 2007",
    "Regulation Number(s)": [
        "21 CFR 866.6010"
    ],
    "Regulation Name(s)": [
        "Tumor-associated antigen immunological test system"
    ],
    "Analyte Class(es)": [
        "immunology",
        "cancer molecular"
    ],
    "Analyte(s)": [
        "CA 15-3 antigen"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Access Immunoassay Systems"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay",
        "Paramagnetic particle-based assay"
    ],
    "Methodologies": [
        "Two-site immunoenzymatic sandwich assay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Calibrator"
    ],
    "Document Summary": "FDA 510(k) summary for Access BR Monitor chemiluminescent immunoassay for quantitative determination of CA 15-3 antigen in serum and plasma to aid breast cancer management",
    "Indications for Use Summary": "For quantitative determination of CA 15-3 antigen levels in human serum and plasma to aid in management of breast cancer patients; serial testing should be used with other clinical methods",
    "fda_folder": "Immunology"
}